Newronika, a leader in adaptive neuromodulation, announced that Lothar Krinke has been named CEO and Director of the Board. Dr. Krinke will be responsible for executing the next phase of Newronika’s strategy to complete full development of its implantable closed-loop neuromodulation platform with an initial clinically proven and market approved indication in Parkinson’s.
Lorenzo Rossi, co-Founder and Board of Directors member, will transition to the critical role of Chief Technology Officer and will lead all aspects of R&D and manufacturing.
“Lothar’s expertise in the field of neuromodulation commercialization, neuroscience and corporate development makes him the ideal professional to lead Newronika as CEO and to ensure that we bring our CE-marked, Alpha-Deep Brain Stimulation System to the US market”, says Lorenzo Rossi.
Lothar has more than 20 years of medical device experience. He was the global General Manager, Brain Modulation, at Medtronic from 2011 to 2017. From 2017 to 2022 he was the CEO of Magstim, the pioneer of transcranial magnetic stimulation.
“Lothar Krinke is an experienced medical device CEO with a specific track record in bringing neuroscience breakthrough therapies to market. We are fortunate we can count on Lothar to bring Newronika to the next level” said Claudio Giuliano, Newronika’s Chairman of the Board of Directors.
Newronika is pioneering the field of closed loop neurotechnology by developing an adaptive deep brain stimulation system (aDBS), and is submitting an investigational device excemption (IDE) for a pivotal trial in Parkinson’s disease. Over the last several years, Newronika has collected pilot data in Europe using its proprietary aDBS technology in Parkinson’s patients. This data has been published in multiple peer reviewed scientific journals.
The company was founded by a multidisciplinary team of neuroscientists led by Dr. Alberto Priori in 2009 with participation from Fondazione IRCCSS Policlinic di Milano and the University of Milano, and is backed by VC investors with a deep healthcare footprint including Innogest Capital, Indaco Venture Partners, Omnes Capital, F3F, Wille Finance and TNBT Capital.
The company has operations in Milan, Italy and Charleston, South Carolina.
Professor Priori who first introduced the concept of adaptive DBS since 2003 says: “I believe that Newronika will rapidly translate the early scientific and clinical data in adaptive deep brain stimulation into a product that has true value for patients, caregivers, clinicians and researchers. Lothar Krinke is the right man at the right time for the company.”
For more information, please visit www.newronika.com or contact Dr. Krinke at [email protected]
